YIH
FDMT icon

Y-Intercept (HK)’s 4D Molecular Therapeutics FDMT Stock Holding History

Y-Intercept (HK)’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-25,420
Closed -$237K – 1852
2026
Q1 		$237K Buy
+25,420
New +$221K ﹤0.01% 1414
2025
Q2 		– Sell
-12,627
Closed -$40.8K – 1735
2025
Q1 		$40.8K Buy
+12,627
New +$59.5K ﹤0.01% 1136
2024
Q4 		– Sell
-24,538
Closed -$265K – 1325
2024
Q3 		$265K Buy
24,538
+11,002
+81% +$183K 0.02% 1063
2024
Q2 		$284K Buy
+13,536
New +$340K 0.02% 1046

Other funds holding FDMT

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
APW
Allied Private Wealth Boca Raton, Florida $156M AUM
FFO
Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

Y-Intercept (HK)'s FDMT Position: Q2 2026 in Review

Y-Intercept (HK) sold out of 4D Molecular Therapeutics (FDMT) in Q2 2026, closing a stake of 25,420 shares — an estimated $237K sold.

Y-Intercept (HK) first reported a position in FDMT in Q2 2024 and held it in 4 quarters. The position peaked at $284K in Q2 2024. 9 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Y-Intercept (HK) reported no remaining 4D Molecular Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Y-Intercept (HK) sold 25,420 4D Molecular Therapeutics shares in Q2 2026, an estimated $237K.
  • Y-Intercept (HK) first reported a position in 4D Molecular Therapeutics in Q2 2024 and held it in 4 quarters.
  • Y-Intercept (HK)'s 4D Molecular Therapeutics position peaked at $284K in Q2 2024.
  • 9 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.